

Product ID D3352 CAS No. 779353-01-4 Chemical Name

Synonym SCH 727965

C ₂₁ H ₂₈ N ₆ O ₂
396.49
≥ 99 %
DMSO 26 mg/mL warmed (65.57 mM) Ethanol 8 mg/mL warmed (20.17 mM) Water Insoluble
-20°C
Ambient
Dinaciclib inhibits CDK1/2/5/9, displa

 Phone:
 888-558-5227

 651-644-8424

 Fax:
 888-558-7329

 Email:
 getinfo@lktlabs.com

 Web:
 lktlabs.com

Product Information



Bulk quanitites available upon request

Product ID	Size
D3352	1 mg
D3352	5 mg
D3352	10 mg

cription Dinaciclib inhibits CDK1/2/5/9, displaying anticancer chemotherapeutic activity. Dinaciclib is currently in clinical trials as a potential treatment for various cancers. In cellular models of acute leukemias, dinaciclib inhibits cell proliferation. In cellular models of pancreatic cancer, this compound inhibits cell proliferation, motility, and colony formation; in vivo, it decreases tumor growth. Dinaciclib also binds BRD proteins.

References Flynn J, Jones J, Johnson AJ, et al. Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print]. PMID: 25708835.

Martin MP, Olesen SH, Georg GI, et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol. 2013 Nov 15;8(11):2360-5. PMID: 24007471.

Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. PMID: 23949430.

Feldmann G, Mishra A, Bisht S, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. PMID: 21768779.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.